Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5215MR)

This product GTTS-WQ5215MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5215MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12595MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ13833MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ10432MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ5005MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ8152MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ11509MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ7719MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ9197MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW